These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 27574402)

  • 1. Pharmacokinetic profile of defibrotide in patients with renal impairment.
    Tocchetti P; Tudone E; Marier JF; Marbury TC; Zomorodi K; Eller M
    Drug Des Devel Ther; 2016; 10():2631-41. PubMed ID: 27574402
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Defibrotide for Patients with Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome: Interim Results from a Treatment IND Study.
    Richardson PG; Smith AR; Triplett BM; Kernan NA; Grupp SA; Antin JH; Lehmann L; Shore T; Iacobelli M; Miloslavsky M; Hume R; Hannah AL; Nejadnik B; Soiffer RJ;
    Biol Blood Marrow Transplant; 2017 Jun; 23(6):997-1004. PubMed ID: 28285079
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Earlier defibrotide initiation post-diagnosis of veno-occlusive disease/sinusoidal obstruction syndrome improves Day +100 survival following haematopoietic stem cell transplantation.
    Richardson PG; Smith AR; Triplett BM; Kernan NA; Grupp SA; Antin JH; Lehmann L; Miloslavsky M; Hume R; Hannah AL; Nejadnik B; Soiffer RJ
    Br J Haematol; 2017 Jul; 178(1):112-118. PubMed ID: 28444784
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Final results from a defibrotide treatment-IND study for patients with hepatic veno-occlusive disease/sinusoidal obstruction syndrome.
    Kernan NA; Grupp S; Smith AR; Arai S; Triplett B; Antin JH; Lehmann L; Shore T; Ho VT; Bunin N; Iacobelli M; Liang W; Hume R; Tappe W; Soiffer R; Richardson P
    Br J Haematol; 2018 Jun; 181(6):816-827. PubMed ID: 29767845
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Defibrotide for the Treatment of Hepatic Veno-Occlusive Disease: Final Results From the International Compassionate-Use Program.
    Corbacioglu S; Carreras E; Mohty M; Pagliuca A; Boelens JJ; Damaj G; Iacobelli M; Niederwieser D; Olavarría E; Suarez F; Ruutu T; Verdonck L; Hume R; Nejadnik B; Lai C; Finetto G; Richardson P
    Biol Blood Marrow Transplant; 2016 Oct; 22(10):1874-1882. PubMed ID: 27397724
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Defibrotide for the treatment of hepatic veno-occlusive disease/sinusoidal obstruction syndrome following nontransplant-associated chemotherapy: Final results from a post hoc analysis of data from an expanded-access program.
    Kernan NA; Richardson PG; Smith AR; Triplett BM; Antin JH; Lehmann L; Messinger Y; Liang W; Hume R; Tappe W; Soiffer RJ; Grupp SA
    Pediatr Blood Cancer; 2018 Oct; 65(10):e27269. PubMed ID: 29873895
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Defibrotide: An Oligonucleotide for Sinusoidal Obstruction Syndrome.
    Aziz MT; Kakadiya PP; Kush SM; Weigel K; Lowe DK
    Ann Pharmacother; 2018 Feb; 52(2):166-174. PubMed ID: 28914546
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The use of defibrotide in blood and marrow transplantation.
    Richardson PG; Carreras E; Iacobelli M; Nejadnik B
    Blood Adv; 2018 Jun; 2(12):1495-1509. PubMed ID: 29945939
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Defibrotide for Sinusoidal Obstruction Syndrome/Veno-Occlusive Disease Prophylaxis in High-Risk Adult Patients: A Single-Center Experience Study.
    Picod A; Bonnin A; Battipaglia G; Giannotti F; Ruggeri A; Brissot E; Malard F; Médiavilla C; Belhocine R; Vekhoff A; Gueye MS; Lapusan S; Adaeva R; Isnard F; Legrand O; Baylatry MT; Joly AC; Labopin M; Duléry R; Mohty M
    Biol Blood Marrow Transplant; 2018 Jul; 24(7):1471-1475. PubMed ID: 29477779
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Defibrotide for children and adults with hepatic veno-occlusive disease post hematopoietic cell transplantation.
    Corbacioglu S; Richardson PG
    Expert Rev Gastroenterol Hepatol; 2017 Oct; 11(10):885-898. PubMed ID: 28825848
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Defibrotide for the treatment of hepatic veno-occlusive disease/sinusoidal obstruction syndrome with multiorgan failure.
    Richardson PG; Grupp SA; Pagliuca A; Krishnan A; Ho VT; Corbacioglu S
    Int J Hematol Oncol; 2017 Nov; 6(3):75-93. PubMed ID: 30302228
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Defibrotide sodium for the treatment of hepatic veno-occlusive disease/sinusoidal obstruction syndrome.
    Richardson PG; Triplett BM; Ho VT; Chao N; Dignan FL; Maglio M; Mohty M
    Expert Rev Clin Pharmacol; 2018 Feb; 11(2):113-124. PubMed ID: 29301447
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of Time to Complete Response after Defibrotide Initiation in Patients with Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome after Hematopoietic Cell Transplantation.
    Richardson PG; Smith AR; Kernan NA; Lehmann L; Ryan RJ; Grupp SA
    Transplant Cell Ther; 2021 Jan; 27(1):88.e1-88.e6. PubMed ID: 32950693
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Defibrotide for Treatment of Severe Veno-Occlusive Disease in Pediatrics and Adults: An Exploratory Analysis Using Data from the Center for International Blood and Marrow Transplant Research.
    Strouse C; Richardson P; Prentice G; Korman S; Hume R; Nejadnik B; Horowitz MM; Saber W
    Biol Blood Marrow Transplant; 2016 Jul; 22(7):1306-1312. PubMed ID: 27108694
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I trial to investigate the effect of renal impairment on isavuconazole pharmacokinetics.
    Townsend RW; Akhtar S; Alcorn H; Berg JK; Kowalski DL; Mujais S; Desai AV
    Eur J Clin Pharmacol; 2017 Jun; 73(6):669-678. PubMed ID: 28271239
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BCSH/BSBMT guideline: diagnosis and management of veno-occlusive disease (sinusoidal obstruction syndrome) following haematopoietic stem cell transplantation.
    Dignan FL; Wynn RF; Hadzic N; Karani J; Quaglia A; Pagliuca A; Veys P; Potter MN; ;
    Br J Haematol; 2013 Nov; 163(4):444-57. PubMed ID: 24102514
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Defibrotide for the management of sinusoidal obstruction syndrome in patients who undergo haemopoietic stem cell transplantation.
    Coutsouvelis J; Avery S; Dooley M; Kirkpatrick C; Spencer A
    Cancer Treat Rev; 2016 Nov; 50():200-204. PubMed ID: 27721142
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness analysis of defibrotide in the treatment of patients with severe veno-occlusive disease/sinusoidal obstructive syndrome with multiorgan dysfunction following hematopoietic cell transplantation in Spain.
    Carcedo Rodriguez D; Artola Urain T; Chinea Rodriguez A; García Torres E; González Vicent M; Gutiérrez García G; Regueiro García A; Calvo Hidalgo M; Villacampa A
    J Med Econ; 2021; 24(1):628-636. PubMed ID: 33858278
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and Safety of Defibrotide for the Treatment of Hepatic Veno-Occlusive Disease after Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-Analysis.
    Yang L; Qi J; Pan T; You T; Ruan C; Han Y
    Semin Thromb Hemost; 2019 Nov; 45(8):767-777. PubMed ID: 31627217
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Systematic Review and Meta-Analysis of Studies of Defibrotide Prophylaxis for Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome.
    Corbacioglu S; Topaloglu O; Aggarwal S
    Clin Drug Investig; 2022 Jun; 42(6):465-476. PubMed ID: 35594010
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.